Store
Global Market for At-Home and Home Collection In Vitro Diagnostic (IVD) Testing, 2025–2030
Publication Date: October 31, 2025
Tags: Coagulation, Diagnostics, Diagnostics Market Research, Drug Testing, Fertility, Genetic Diseases, Glucose, HbA1c, In Vitro Diagnostics (IVD), Infectious Diseases, IVD, Pregnancy
Pages: 125
SKU: 25-076KA
The convenience revolution in healthcare has arrived—and diagnostics are at the center of it. The Global Market for At-Home and Home Collection In Vitro Diagnostic (IVD) Testing, 2025–2030 provides a comprehensive analysis of one of the fastest-evolving sectors of the diagnostics industry. Covering both self-administered over-the-counter (OTC) tests and home collection kits analyzed in central laboratories, this Kalorama Information report examines the technologies, market forces, and consumer behaviors transforming how patients engage with testing and care.
For diagnostic developers, investors, and healthcare strategists, The Global Market for At-Home and Home Collection In Vitro Diagnostic (IVD) Testing, 2025–2030 provides the essential insight needed to understand how home diagnostics are moving beyond niche applications to become a core component of modern healthcare delivery—and a key driver of the global IVD market’s future growth.
Building on the momentum sparked by the COVID-19 pandemic, the report explores how growing public confidence in self-testing is reshaping the landscape of infectious disease detection, chronic disease management, oncology, genetic testing, and wellness screening. While glucose monitoring and pregnancy testing continue to anchor the category, innovations in non-invasive sampling methods—from saliva and urine to breath analysis—are enabling a broader range of tests to move from clinic to home.
The global Home IVD testing market is segmented into several broad areas, including:
- Genetic
- Glucose/ HbA1c
- Infectious disease
- Other areas
- Pregnancy and Fertility
- Coagulation
- Fecal Occult Blood
- Cholesterol
- Drugs of Abuse
Each market segment includes a detailed analysis of regulatory trends, clinical practices, and recent product approvals, along with 2025 sales data and forecasts through 2030 across major world regions, including the United States, EMEA, Asia Pacific, and the Rest of World. The study profiles key market leaders and emerging competitors, evaluating how technological advances, consumer acceptance, and cost considerations will drive growth and shape competition.
The report also distinguishes between the two major segments:
- At-Home IVD Tests – fully self-administered tests providing immediate results (e.g., pregnancy and glucose monitoring).
- Home Collection IVD Tests – tests where patients collect samples and send them to a laboratory for analysis (e.g., fecal occult blood, genetic, and infectious disease testing).
Scope and Methodology
Using a combination of primary interviews and secondary research, the report delivers reliable market sizing, competitive intelligence, and growth projections based on 2025 as the base year. Forecasts through 2030 include compound annual growth rates (CAGRs) and regional performance indicators.
Despite the growing demand, the report also acknowledges ongoing challenges in cost-benefit analysis, reimbursement models, and regulatory and privacy frameworks that may shape the pace of adoption.
Chapter 1: Executive Summary
Industry at a Glance
Size and Growth of the Market
- Figure 1-1: Global Home IVD Market by Key Segment, 2022-2025 ($ million) [Genetic, Glucose/HbA1c, Infectious Disease, Other Areas]
Key Issues and Trends Affecting the Market
Competitive Outlook
Conclusion Highlights
About Kalorama Information
Chapter 2: Introduction
Home IVD Testing Overview
Market Segments
Market Evolution
Historical Context
Market Drivers
Key Players
Issues and Trends
COVID-19 Evolution
- Figure 2-1: Home COVID-19 Test Distribution of Sales, by Vendor, 2025 (%)
Reimbursement for Home Tests
Continuous Glucose Monitors
- Figure 2-2: Continuous Glucose Monitor Access for Medicaid Beneficiaries Living with Diabetes: State-By-State Coverage
Infectious Disease
Cancer
Chronic Disease Monitoring
Genetic
Home IVD Testing Drivers and Challenges
- Figure 2-3: Benefits and Challenges to Home Testing, 2025
Key Benefits of Home Testing
Key Challenges of Home Testing
Genetics
- Table 2-1: Home Genetic Laboratory Testing, Market Drivers and Barriers
Home Collection
Chapter 3: At-Home IVD Tests
Introduction
Diabetes
- Table 3-1: Selected Glucose At-Home Testing Meter Innovations
Pregnancy and Fertility
Infectious Disease
HIV
COVID-19 & Flu
- Table 3-2: Selected Molecular COVID-19 and COVID-19 & Flu A/B At-Home Tests for SARS-CoV-2, 2024-2025
- Table 3-3: Selected Antigen COVID- 19 and COVID-19 & Flu A/B At-Home Tests for SARS-CoV-2, 2024-2025
Coagulation
Fecal Occult Blood
Cholesterol
Drugs of Abuse
At-Home IVD Test Market by Test Type
- Table 3-4: Global At-Home IVD Market, by Test Type, 2025 ($ billion) [Glucose, Infectious Disease, Other]
- Figure 3-1: Global At-Home IVD Market by Distribution of Sales, by Segment, 2025 (%) [Cholesterol, Coagulation, COVID-19+, Drug of Abuse, FOB, Glucose, HIV, Other Infections, Pregnancy & Fertility, Other]
At-Home IVD Tests Market by Sample Type
- Table 3-5: Global At-Home IVD Market, by Sample Type, 2025 ($ billion) [Blood, Interstitial Fluid, Nasal, Oral/Saliva, Stool, Urine, Other]
- Figure 3-2: Global At-Home IVD Market by Distribution of Sales, by Sample Type, 2020 and 2025 (%) [Blood, Interstitial Fluid, Nasal, Oral/Saliva, Stool, Urine, Other]
- Figure 3-3: Year-over-Year Growth for At-Home IVD Markets, ’23-24 & ’24-25 (%) [Cholesterol, Coagulation, COVID-19, Drugs of Abuse, Fecal Occult Blood (FOB), Glucose, HIV, Infectious Disease, Pregnancy & Fertility, Other]
Blood Samples
- Figure 3-4: Estimated Distribution of Blood Sample Sales, by Test Type, 2025 (%) [Cholesterol, Coagulation, Glucose, Other]
Interstitial Fluid Samples
Urine Samples
- Figure 3-5: Estimated Distribution of Urine Sample Sales, by Test Type, 2025 (%) [Drugs of Abuse, Infectious Disease, Pregnancy, Other]
Oral/Saliva Samples
- Figure 3-6: Estimated Distribution of Oral/Saliva Sample Sales, by Test Type, 2025 (%) [COVID-19, Drugs of Abuse, HIV, Other]
Nasal Samples
- Figure 3-7: Estimated Distribution of Nasal Sample Sales, by Test Type, 2025 (%) [COVID-19, Other]
Stool Samples
- Figure 3-8: Estimated Distribution of Stool Sample Sales, by Test Type, 2025 (%) [Fecal Occult Blood (FOB), Other]
Other
Chapter 4: Home Collection IVD Tests
Introduction
Pregnancy and Fertility
Infectious Disease
HIV
HPV and Other STDs
Hepatitis
COVID-19
COVID-19 & Flu
Fecal Occult Blood
Cholesterol
Genetics
Other
Home Collection IVD Test Market by Test Type
- Table 4-1: Global Home Collection IVD Market, by Test Type, 2025 ($ billion) [Genetics, Infectious Disease, Other Areas]
- Figure 4-1: Global Home IVD Market by Distribution of Sales, by Segment, 2025 (%) [Cholesterol, Coagulation, COVID-19, Drug of Abuse, FOB, Glucose, HbA1c, HIV, Other Infections, Pregnancy & Fertility, Other]
Privacy Genetic Testing
Home Collection Tests Market by Sample Type
- Table 4-2: Global Home Collection IVD Market, by Sample Type, 2025 ($ billion) [Blood, Nasal, Oral/Saliva, Stool, Urine, Other]
- Figure 4-2: Global Home Collection IVD Market by Distribution of Sales, by Sample Type, 2020 and 2025 (%) [Blood, Nasal, Oral/Saliva, Stool, Urine, Other]
- Figure 4-3: Year-over-Year Growth for Home Collection IVD Markets, ’23-24 and ’24-25 (%) [Cholesterol, Coagulation, COVID-19, Drugs of Abuse, Fecal Occult Blood (FOB), Genetic, HbA1c, HIV, Infectious Disease, Pregnancy & Fertility, Other]
Blood Samples
- Figure 4-4: Estimated Distribution of Blood Sample Sales, by Test Type, 2025 (%) [Cholesterol, Fertility, Genetic, Glucose/HbA1c, Infectious Disease – STD Blood Spot, Tumor Marker – PSA Blood Spot, Other – Hormone]
Urine Samples
- Figure 4-5: Estimated Distribution of Urine Sample Sales, by Test Type, 2025 (%) [Infectious Disease – STD, Pregnancy/Fertility, Other – Heavy Metals, Hormone, Nutrition]
Oral/Saliva Samples
- Figure 4-6: Estimated Distribution of Oral/Saliva Sample Sales, by Test Type, 2025 (%) [COVID-19, Drugs of Abuse, Fertility, Genetic, HIV, Other – Hormone, Nutrition, Medication Match]
Nasal Samples
- Figure 4-7: Estimated Distribution of Nasal Sample Sales, by Test Type, 2025 (%) [COVID-19, Other]
Stool Samples
- Figure 4-8: Estimated Distribution of Stool Sample Sales, by Test Type, 2025 (%) [Fecal Occult Blood (FOB), Infectious Disease – Pathogen ID, Other – Heavy Metals]
Other
Chapter 5: Market Participants
23andMe, Inc
- Table 5-1: 23andMe Corporate Summary
Company Overview
- Table 5-2: 23andMe Genetic Tests with FDA Marketing Authorization
Abbott Diagnostics
- Table 5-3: Corporate Summary
Company Overview
Performance Review
- Table 5-4: Abbott Revenues, 2020-2024 ($ million)
Abingdon Health Ltd.
- Table 5-5: Abingdon Health Corporate Summary
Company Overview
ACON Laboratories, Inc.
- Table 5-6: ACON Laboratories Corporate Summary
Company Overview
ARKRAY, Inc.
- Table 5-7: ARKRAY Corporate Summary
Company Overview
Ascensia Diabetes Care Holdings AG
- Table 5-8: Ascensia Diabetes Care Corporate Summary
Company Overview
Atomo Diagnostics
- Table 5-9: Atomo Corporate Summary
Company Overview
Becton Dickinson
- Table 5-10: Becton Dickinson Corporate Summary
Company Overview
Performance Review
- Table 5-11: BD Corporation Revenue, 2020-2024 ($ billion)
binx health
- Table 5-12: binx health Corporate Summary
Company Overview
Biomerica, Inc.
- Table 5-13: Biomerica Corporate Summary
Company Overview
Company Financials
- Table 5-14: Biomerica Corporation Revenue, 2020-2024 ($ million)
Biosynex SA
- Table 5-15: Biosynex Corporate Summary
Company Overview
Church & Dwight Co. Inc
- Table 5-16: Church & Dwight Corporate Summary
Company Overview
Performance Review
- Table 5-17: Church and Dwight Revenues, 2020-2024 ($ million)
Color Health, Inc.
- Table 5-18: Color Health Corporate Summary
Company Overview
Dexcom, Inc.
- Table 5-19: Dexcom Corporation Corporate Summary
Company Overview
Performance Review
- Table 5-20: Dexcom Revenues, 2020-2024 ($ million)
EasyDNA
- Table 5-21: EasyDNA Corporate Summary
Company Overview
Everly Health
- Table 5-22: Everly Health Corporate Summary
Company Overview
Exact Sciences
- Table 5-23: Exact Sciences Corporate Summary
Company Overview
Performance Review
- Table 5-24: Exact Sciences Revenues (2020-2024) ($ million)
GeneDx
- Table 5-25: GeneDx Corporate Summary
Company Overview
Helena Laboratories
- Table 5-26: Helena Laboratories Corporate Summary
Company Overview
Hemosure, Inc.
- Table 5-27: Hemosure Corporate Summary
Company Overview
Laboratory Corporation of America
- Table 5-28: Laboratory Corporation of America Corporate Details
Company Overview
Performance Review
- Table 5-29: Labcorp Revenue History, 2020-2024 ($ million)
Medichecks.com Ltd.
- Table 5-30: Medichecks Corporate Summary
Company Overview
Myriad Genetics, Inc.
- Table 5-31: Myriad Genetics Corporate Summary
Company Overview
Performance Review
- Table 5-32: Myriad Diagnostics Revenue, 2020-2024 ($ million)
Natera
- Table 5-33: Natera Corporate Summary
Company Overview
Performance Review
- Table 5-34: Natera Revenue History, 2020-2024 ($ million)
OraSure Technologies, Inc.
- Table 5-35: OraSure Technologies Summary
Company Overview
Performance Review
- Table 5-36: OraSure Revenues, 2020-2024 ($ million)
Polymedco, Inc
- Table 5-37: Polymedco Corporate Summary
Company Overview
Preventis GmbH
- Table 5-38: Preventis Corporate Summary
Company Overview
Prima Lab SA
- Table 5-39: Prima Corporate Summary
Company Overview
Quest Diagnostics, Inc.
- Table 5-40: Quest Diagnostics Corporate Details
Company Overview
Performance Review
- Table 5-41: Quest Diagnostics Revenue History, 2020-2024 ($ million)
QuidelOrtho Corporation
- Table 5-42: QuidelOrtho Corporate Summary
Company Overview
Performance Review
- Table 5-43: QuidelOrtho Revenues, 2020-2024 ($ million)
Roche Diagnostic Corporation
- Table 5-44: Roche Diagnostic Corporate Summary
Company Overview
Performance Review
- Table 5-45: Roche Diagnostics, 2020-2024 (CHF billion)
Siemens Healthineers GmbH
- Table 5-46: Siemens Healthineers Corporate Summary
Company Overview
Performance Review
- Table 5-47: Siemens Healthineers Revenue History, 2020-2024 (€ million)
Swiss Precision Diagnostics GmbH
- Table 5-48: Swiss Precision Diagnostics Corporate Summary
Company Overview
Trividia Health
- Table 5-49: Trividia Health Corporate Summary
Company Overview
VedaLab
- Table 5-50: VedaLab Corporate Summary
Company Overview
Chapter 6: Market Analysis
Market Overview
- Figure 6-1: Global Home IVD Market, 2025-2030 ($ million) [Genetic, Infectious Disease, Other Areas]
Market Segment by Test Type
- Figure 6-2: Global Home IVD Market by Test Type, 2022-2025 ($ million) [Genetic, Glucose/HbA1c, Infectious Disease, Other Areas]
- Figure 6-3: Global Home IVD Market, by General Test Segment, 2025 (%) [Genetic, Glucose/HbA1c, Infectious Disease, Other Areas]
Glucose & HbA1c
- Table 6-1: Estimated Global Home IVD Glucose & HbA1c Testing Market, 2025-2030 ($ million)
Infectious Disease
- Table 6-2: Estimated Global Home IVD Infectious Disease Testing Market, 2025-2030 ($ million)
Genetic
- Table 6-3: Estimated Global Home IVD Genetic Testing Market, 2025-2030 ($ million)
Other Areas
- Table 6-4: Estimated Global Home IVD Other Testing Market, 2025-2030 ($ million)
Market by Distribution
Market by Region
- Figure 6-4: Estimated Global Home IVD Testing Market, by Region, 2023-2025 ($ million) [APAC, EMEA, United States, Rest of World]
Competitive Analysis
- Figure 6-5: Estimated Global Home IVD Testing Market, Top Vendor Market Share, 2025 (%)
Related products
Cell and Gene Therapy Deals Analysis, 2021-2024
June 3, 2024
Kalorama Information’s Cell and Gene Therapy Deals Analysis: Financings, Partnering, M&A, Tech Transfers, IPOs/SPACs, Other Deals, 2021-2024 offers a comprehensive look at the dynamic and rapidly evolving cell and gene therapy market. This report highlights the significant deal-making activities that have taken place from Q1 2021 to Q1 2024, providing valuable insights for companies and…
Price range: $6,300.00 through $9,450.00
30-Country IVD Market Atlas, 2024
December 23, 2024
With over two decades of experience in publishing in vitro diagnostic (IVD) market research, Kalorama Information presents the 30 Country In Vitro Diagnostics (IVD) Market Atlas, 2024. This quarterly updated report offers a unique approach focused on country-level research and analysis, providing a detailed analysis of major IVD segments forecasted for five years…
Price range: $5,000.00 through $7,875.00
The World Market for Vaccines, 2024
February 22, 2024
Vaccines are a cornerstone of preventive medicine, offering long-term or permanent immunity against diseases. They have been instrumental in near-eliminating many deadly diseases, making vaccination one of the greatest public health achievements of the 20th century. Kalorama Information’s latest report, The World Market for Vaccines, 2024, provides a comprehensive analysis of adult…
Price range: $5,000.00 through $7,875.00
